AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast cancer ...
Oct 6 (Reuters) - AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab precision drug Datroway improved survival prospects in patients with an advanced form of breast cancer ...
Results indicated that the Enhertu combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 ...
AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost 15% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results